INNT
TOTAL INVALIDATION PROCESSED BY THE IB
01/24/2025
Back to search
Official data from USPTO
CANSINOBIO
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
01/25/2025
Classification
Registered
Trademark type
Combined
Nice classes
5
Filing date
10/11/2016
Registration date
09/12/2017
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/29/2024
Last transaction
01/25/2025
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
5
Owner type
03
Owner location
CN
Examiner
BULLOFF, TOBY
Law office
N10
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "CANSINOBIO" in stylized font.
Holders and representatives
Holders
Tianjin CanSino Biotechnology Inc.
Representatives
Tianjin Brighthead Intellectual Property Co., Ltd.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations, namely, antivirals, antibodies for treatment in disease, tumor suppressing agents, for the treatment of infectious diseases and inflammation, and for the detection and treatment of cancer; Chemico-pharmaceutical preparations, namely, antivirals, tumor suppressing agents, for the treatment of infectious diseases and inflammation, and for the detection and treatment of cancer; Vaccines; Drugs for medical purposes, namely, antivirals, antibodies for treatment in disease, tumor suppressing agents, for the treatment of infectious diseases and inflammation, and for the detection and treatment of cancer; Media for bacteriological cultures; Chemical preparations for medical purposes, namely, antivirals, tumor suppressing agents, for the treatment of infectious diseases and inflammation, and for the detection and treatment of cancer; Cultures of microorganisms for medical and veterinary use
Publications
History of USPTO decisions and trademark events.
25 publications found
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
01/03/2025
INPC
INVALIDATION PROCESSED
01/02/2025
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
11/30/2024
C71T
CANCELLED SECTION 71
03/29/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/27/2018
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/20/2017
FIMP
FINAL DISPOSITION PROCESSED
12/20/2017
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/12/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
09/12/2017
PUBO
PUBLISHED FOR OPPOSITION
06/27/2017
NPUB
NOTICE OF PUBLICATION
06/07/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/19/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/18/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/18/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/18/2017
RFNT
REFUSAL PROCESSED BY IB
02/24/2017
MAFR
APPLICATION FILING RECEIPT MAILED
02/11/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/08/2017
RFRR
REFUSAL PROCESSED BY MPU
02/08/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/08/2017
CNRT
NON-FINAL ACTION WRITTEN
02/07/2017
DOCK
ASSIGNED TO EXAMINER
02/07/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/07/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/02/2017
Continuous trademark protection
Get notified about every new filing that threatens CANSINOBIO or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.